Page 88 - Read Online

Pazgan-Simon. Hepatoma Res 2020;6:17 I http://dx.doi.org/10.20517/2394-5079.2019.52 Page 7 of 8

Table 4. Clinical risk factors of carcinogenesis in patients treated with DAA
Clinical risk factors of carcinogenesis in patients treated with DAA
Previous history of HCC
Cirrhosis
Male sex
Hypoalbuminaemia
Thrombocytopaenia
Elevated AFP levels
DAA: direct acting antiviral; HCC: hepatocellular carcinoma

CONCLUSION
The natural course of HCV infection may lead to the development of HCC in some cases. DAA therapy
reduced risk of HCV related HCC and death. But in some cases HCV therapy is related with liver cancer
development. Patients after DAA treatment, mainly with liver cirrhosis, require HCC surveillance.

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. The World Organization. Hepatits C fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
07.04.202. [Last accessed on 7 Apr 2020]
2. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiretroviral therapy for hepatits virus C
infection. Nat Rev Microbiol 2013;11:482-96.
3. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalps B, et al. Genome-wide association study identifies variants associated with progression
of liver fibrosis from HCV infection. Gastroenterology 2012;143:1244-52.e12.
4. Westbrook RH, Dusheiko G. Natural history of hepatits C. J Hepatol 2014;61:58-68.
5. Nault JC, Mallet M, Pilati C, Calderano J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic
mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2281.
6. Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of 53 transcription regulatory activity and post-translational modification by
hepatits C virus core protein. Oncogene 2004;23:2472-83.
7. European Association for the Study of the Liver. EASL recommendation on treatment of hepatits C 2018. J Hepatol 2018;69:461-511.
8. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American association for the
study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus